vs

Side-by-side financial comparison of BANCFIRST CORP (BANF) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

BANCFIRST CORP is the larger business by last-quarter revenue ($181.0M vs $151.7M, roughly 1.2× Tarsus Pharmaceuticals, Inc.). BANCFIRST CORP runs the higher net margin — 32.9% vs -5.5%, a 38.4% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 11.1%). BANCFIRST CORP produced more free cash flow last quarter ($237.0M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 9.5%).

BancFirst Corporation is an Oklahoma-based financial services holding company. The company operates three subsidiary banks, BancFirst, an Oklahoma state-chartered bank; and Pegasus Bank and Worthington Bank, both Texas state-chartered banks.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

BANF vs TARS — Head-to-Head

Bigger by revenue
BANF
BANF
1.2× larger
BANF
$181.0M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+117.3% gap
TARS
128.4%
11.1%
BANF
Higher net margin
BANF
BANF
38.4% more per $
BANF
32.9%
-5.5%
TARS
More free cash flow
BANF
BANF
$224.0M more FCF
BANF
$237.0M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
9.5%
BANF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BANF
BANF
TARS
TARS
Revenue
$181.0M
$151.7M
Net Profit
$59.5M
$-8.4M
Gross Margin
Operating Margin
41.6%
-5.3%
Net Margin
32.9%
-5.5%
Revenue YoY
11.1%
128.4%
Net Profit YoY
5.3%
63.8%
EPS (diluted)
$1.75
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BANF
BANF
TARS
TARS
Q4 25
$181.0M
$151.7M
Q3 25
$175.5M
$118.7M
Q2 25
$169.3M
$102.7M
Q1 25
$164.8M
$78.3M
Q4 24
$162.9M
$66.4M
Q3 24
$163.7M
$48.1M
Q2 24
$153.8M
$40.8M
Q1 24
$151.0M
$27.6M
Net Profit
BANF
BANF
TARS
TARS
Q4 25
$59.5M
$-8.4M
Q3 25
$62.7M
$-12.6M
Q2 25
$62.3M
$-20.3M
Q1 25
$56.1M
$-25.1M
Q4 24
$56.5M
$-23.1M
Q3 24
$58.9M
$-23.4M
Q2 24
$50.6M
$-33.3M
Q1 24
$50.3M
$-35.7M
Operating Margin
BANF
BANF
TARS
TARS
Q4 25
41.6%
-5.3%
Q3 25
45.0%
-12.2%
Q2 25
47.1%
-21.6%
Q1 25
43.1%
-33.5%
Q4 24
44.2%
-36.8%
Q3 24
45.2%
-52.3%
Q2 24
42.4%
-81.6%
Q1 24
42.5%
-136.5%
Net Margin
BANF
BANF
TARS
TARS
Q4 25
32.9%
-5.5%
Q3 25
35.7%
-10.6%
Q2 25
36.8%
-19.8%
Q1 25
34.0%
-32.1%
Q4 24
34.7%
-34.8%
Q3 24
36.0%
-48.7%
Q2 24
32.9%
-81.6%
Q1 24
33.3%
-129.4%
EPS (diluted)
BANF
BANF
TARS
TARS
Q4 25
$1.75
$-0.17
Q3 25
$1.85
$-0.30
Q2 25
$1.85
$-0.48
Q1 25
$1.66
$-0.64
Q4 24
$1.68
$-0.57
Q3 24
$1.75
$-0.61
Q2 24
$1.51
$-0.88
Q1 24
$1.50
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BANF
BANF
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$1.9B
$343.4M
Total Assets
$14.8B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BANF
BANF
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
BANF
BANF
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
BANF
BANF
TARS
TARS
Q4 25
$1.9B
$343.4M
Q3 25
$1.8B
$335.1M
Q2 25
$1.7B
$332.6M
Q1 25
$1.7B
$342.5M
Q4 24
$1.6B
$224.5M
Q3 24
$1.6B
$237.5M
Q2 24
$1.5B
$252.2M
Q1 24
$1.5B
$275.2M
Total Assets
BANF
BANF
TARS
TARS
Q4 25
$14.8B
$562.2M
Q3 25
$14.2B
$534.6M
Q2 25
$14.0B
$495.0M
Q1 25
$14.0B
$500.8M
Q4 24
$13.6B
$377.0M
Q3 24
$13.3B
$376.3M
Q2 24
$12.7B
$376.8M
Q1 24
$12.6B
$349.3M
Debt / Equity
BANF
BANF
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BANF
BANF
TARS
TARS
Operating Cash FlowLast quarter
$285.3M
$19.3M
Free Cash FlowOCF − Capex
$237.0M
$13.0M
FCF MarginFCF / Revenue
130.9%
8.6%
Capex IntensityCapex / Revenue
26.7%
4.2%
Cash ConversionOCF / Net Profit
4.79×
TTM Free Cash FlowTrailing 4 quarters
$430.7M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BANF
BANF
TARS
TARS
Q4 25
$285.3M
$19.3M
Q3 25
$75.4M
$18.3M
Q2 25
$78.1M
$-29.4M
Q1 25
$77.0M
$-20.7M
Q4 24
$261.2M
$-22.2M
Q3 24
$77.6M
$-8.7M
Q2 24
$100.2M
$-14.4M
Q1 24
$66.3M
$-37.8M
Free Cash Flow
BANF
BANF
TARS
TARS
Q4 25
$237.0M
$13.0M
Q3 25
$63.7M
$16.3M
Q2 25
$64.4M
$-30.4M
Q1 25
$65.6M
$-21.2M
Q4 24
$224.5M
$-22.3M
Q3 24
$72.4M
$-8.9M
Q2 24
$94.1M
$-15.4M
Q1 24
$56.1M
$-38.0M
FCF Margin
BANF
BANF
TARS
TARS
Q4 25
130.9%
8.6%
Q3 25
36.3%
13.8%
Q2 25
38.0%
-29.6%
Q1 25
39.8%
-27.1%
Q4 24
137.8%
-33.5%
Q3 24
44.2%
-18.6%
Q2 24
61.2%
-37.8%
Q1 24
37.1%
-137.5%
Capex Intensity
BANF
BANF
TARS
TARS
Q4 25
26.7%
4.2%
Q3 25
6.7%
1.6%
Q2 25
8.1%
1.0%
Q1 25
6.9%
0.8%
Q4 24
22.5%
0.1%
Q3 24
3.2%
0.6%
Q2 24
3.9%
2.5%
Q1 24
6.8%
0.6%
Cash Conversion
BANF
BANF
TARS
TARS
Q4 25
4.79×
Q3 25
1.20×
Q2 25
1.25×
Q1 25
1.37×
Q4 24
4.62×
Q3 24
1.32×
Q2 24
1.98×
Q1 24
1.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons